Immunology and Microbiology
Plasmodium falciparum
100%
Blood Plasma
70%
COVID-19
58%
Plasmodium
50%
Severe Acute Respiratory Syndrome Coronavirus 2
45%
Hemozoin
44%
Antimalarial Agent
24%
Gametocyte
21%
Chloroquine
20%
Erythrocyte
20%
Prevalence
19%
Monospecific Antibody
19%
Neutralizing Antibody
17%
Heme
16%
Polymerase Chain Reaction
15%
Plasmodium vivax
14%
Parasitemia
14%
Neutralization
13%
Spike
11%
Titer
11%
Desorption
11%
Plasmodium berghei
11%
Sporozoite
10%
Vaccine Efficacy
9%
Antibody Titer
9%
Malaria Control
9%
Antibody Response
9%
Monoclonal Antibody
9%
Human Immunodeficiency Virus 1
8%
Real Time Polymerase Chain Reaction
8%
Mouse
8%
ELISA
8%
Anopheles
7%
Pharmacokinetics
7%
Human Immunodeficiency Virus
7%
Protein Degradation
6%
Omicron Coronavirus Variant
6%
Polymerase Chain Reaction
6%
Atovaquone
6%
Pyrimethamine
5%
Antimalarial Activity
5%
Bagg Albino Mouse
5%
Cerebrospinal Fluid
5%
Vaccination Policy
5%
Protozoa
5%
Cytokine
5%
Mouse Model
5%
Macrophage
5%
Keyphrases
Convalescent Plasma
62%
COVID-19
45%
Plasmodium Falciparum
44%
Malaria
31%
COVID-19 Convalescent Plasma
23%
Hemozoin
22%
Histidine-rich Protein 2 (HRP2)
14%
Chloroquine
14%
Heme
12%
Plasmodium
11%
Bangladesh
11%
Hill District
11%
Chittagong
11%
Meta-analysis
11%
Hospitalization
11%
Malaria Parasite
11%
Rapid Diagnostic Test
10%
Convalescent Plasma Donors
10%
Asymptomatic Malaria
9%
Antibody Level
9%
Hospitalized Patients
9%
Parasitemia
9%
Antimalarial Drugs
9%
Pregnant Women
9%
Transfusion
9%
Randomized Trial
8%
Systematic Meta-analysis
8%
Plasmodium Infection
8%
Hemoglobin
8%
Artemisinin
8%
Falciparum Malaria
8%
Plasmodium Berghei
7%
Malaria Diagnosis
7%
Gametocyte
7%
Pyronaridine
6%
Pharmacodynamics
6%
High Titer
6%
Brain Endothelium
6%
Convalescent Plasma Therapy
6%
Malaria Transmission
6%
Passive Immunity
6%
Malaria Infection
6%
United States
6%
Malaria pigment
6%
Digestive Vacuole
6%
Virus-neutralizing Antibody
5%
Drug Library
5%
Persisters
5%
Rwanda
5%
Infected Erythrocytes
5%
Pharmacology, Toxicology and Pharmaceutical Science
Plasmodium falciparum
54%
Antimalarial Agent
44%
Infection
30%
Convalescence
27%
Hemozoin
25%
Disease
25%
Plasmodium
23%
Malaria Falciparum
22%
Heme
21%
Artemisinin
19%
Chloroquine
16%
Coronavirinae
13%
Prevalence
13%
Mouse
13%
Dimer
12%
Randomized Controlled Trial
11%
SARS Coronavirus
11%
Histidine
10%
Parasitemia
9%
Anemia
9%
Symptom
9%
Antimalarial Activity
8%
Monoclonal Antibody
8%
Pyrimethamine
7%
Pharmacokinetics
7%
Nanoparticle
7%
Drug Discovery
7%
Crystallization
7%
Immunocompromised Patient
7%
Combination Therapy
7%
Malaria
6%
Hematin
6%
Pyronaridine
6%
Quinoline Derivative
6%
Antivirus Agent
6%
Nanobubble
5%
Transdermal
5%
Hepcidin
5%
Azithromycin
5%
Cerebral Malaria
5%
Rodent Malaria
5%
Clinical Trial
5%
Mefloquine
5%
Plasmodium berghei
5%
Dihydrofolate Reductase
5%